News

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for XALKORI^® (crizotinib) for the treatment of

Regulatory News:

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces the appointment of Gaëlle Stadtler as

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a strategic partnership with JADE Biomedical (JADE), a provider of end-to-end quality management

Regulatory News:

GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies

Pfizer Inc. (NYSE: PFE) today announced that, during the second half of 2020, it invested a total of $120 million in four clinical-stage biotech companies as part of the Pfizer Breakthrough Growth

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended December 31, 2020. The financial information

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at the 39^th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12^th, at 10:00

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today provided a corporate

VALBIOTIS (FR0013254851 – ALVAL / qualifiziert für PEA/SME) (Paris:ALVAL), ein französisches Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung

Novocure (NASDAQ: NVCR) today reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2020. Novocure plans to discuss these

Regulatory News:

Lysogene (Paris:LYS) (FR0013233475 – LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announces that it has received MHRA and

Regulatory News:

VALBIOTIS (FR0013254851 – ALVAL / eligible for the PEA/SME) (Paris:ALVAL), a French Research & Development company committed to scientific innovation for preventing and combating

NANOBIOTIX (Paris:NANO) (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a clinical-stage biotechnology company focused on developing first-in-class product candidates that use proprietary

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Berufung von Dr. Toralf Haag in den Aufsichtsrat mit sofortiger Wirkung bekannt. Dr. Haag wird gleichzeitig Mitglied des

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that Dr. Toralf Haag has been appointed a member of the Supervisory Board with immediate effect. He will also become a member of

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the management team will participate in two upcoming virtual investor conferences and

ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today

Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 CIFFREO study, which will evaluate the efficacy and safety of investigational gene therapy candidate

Regulatory News:

Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and The University of Texas

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Chief Financial Officer Sung Lee is leaving the Company to pursue a new opportunity overseas. Mr. Lee’s

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to two webcasts of discussions with Pfizer leadership at the 39^th Annual J.P. Morgan Healthcare Conference to be held

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present a corporate overview at the 39^th Annual J.P. Morgan Healthcare Conference on